The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity?
Daniel Louis Hertz
No relevant relationships to disclose
Anna C. Snavely
No relevant relationships to disclose
James P Evans
No relevant relationships to disclose
Joseph G Ibrahim
No relevant relationships to disclose
Steven M. Anderson
Employment or Leadership Position - LabCorp
Kenneth J Friedman
Employment or Leadership Position - LabCorp
Karen E Weck
No relevant relationships to disclose
Peter Rubin
No relevant relationships to disclose
Oludamilola A. Olajide
No relevant relationships to disclose
Susan G. Moore
No relevant relationships to disclose
Rachel Elizabeth Raab
No relevant relationships to disclose
Daniel R. Carrizosa
No relevant relationships to disclose
Steven William Corso
No relevant relationships to disclose
Garry Schwartz
No relevant relationships to disclose
Jeffrey M. Peppercorn
No relevant relationships to disclose
Mark Graham
No relevant relationships to disclose
Sean Thomas Canale
No relevant relationships to disclose
Howard L. McLeod
No relevant relationships to disclose
Lisa A. Carey
No relevant relationships to disclose
William Johnson Irvin
No relevant relationships to disclose